Patents by Inventor Richard Rutter

Richard Rutter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 12630516
    Abstract: The invention relates to compounds of formula (I): and related aspects.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: May 19, 2026
    Assignee: NRG THERAPEUTICS LTD.
    Inventors: Neil Miller, Richard Rutter, Jan Kulagowski, Richard Morphy, Tammy Ladduwahetty, John Maclean, Mustafa Moroglu, Eric Talbot, Michael Rowley
  • INHIBITORS OF MPTP
    Publication number: 20260007672
    Abstract: The invention relates to compounds of formula (I), and related aspects.
    Type: Application
    Filed: September 9, 2025
    Publication date: January 8, 2026
    Applicant: NRG Therapeutics Ltd
    Inventors: Neil MILLER, Gilles OUVRY, Richard RUTTER, Tammy LADDUWAHETTY, Christopher THOMSON, Jan KULAGOWSKI, Michael ROWLEY, Andrew TUFFNELL, Gabriel NEGOITA-GIRAS, Mark STEWART, Rachel ARMSTRONG, Susan BOYD
  • Acrylamide derivatives
    Patent number: 12497359
    Abstract: The invention relates to compounds of formula (I) and related aspects.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: December 16, 2025
    Assignee: NRG THERAPEUTICS LTD
    Inventors: Neil Miller, Richard Rutter, Jan Kulagowski, Richard Morphy, Tammy Ladduwahetty, John MacLean, Eric Talbot
  • Inhibitors of mPTP
    Patent number: 12491185
    Abstract: The invention relates to compounds of formula (I), and related aspects.
    Type: Grant
    Filed: January 16, 2025
    Date of Patent: December 9, 2025
    Assignee: NRG THERAPEUTICS LTD
    Inventors: Neil Miller, Gilles Ouvry, Richard Rutter, Tammy Ladduwahetty, Christopher Thomson, Jan Kulagowski, Michael Rowley, Andrew Tuffnell, Gabriel Negoita-Giras, Mark Stewart, Rachel Armstrong, Susan Boyd
  • INHIBITORS OF MPTP
    Publication number: 20250177397
    Abstract: The invention relates to compounds of formula (I), and related aspects.
    Type: Application
    Filed: January 16, 2025
    Publication date: June 5, 2025
    Applicant: NRG Therapeutics Ltd
    Inventors: Neil MILLER, Gilles OUVRY, Richard RUTTER, Tammy LADDUWAHETTY, Christopher THOMSON, Jan KULAGOWSKI, Michael ROWLEY, Andrew TUFFNELL, Gabriel NEGOITA-GIRAS, Mark STEWART, Rachel ARMSTRONG, Susan BOYD
  • ACRYLAMIDE COMPOUNDS
    Publication number: 20250179028
    Abstract: The invention relates to compounds of formula (I): (I) and related aspects.
    Type: Application
    Filed: March 2, 2023
    Publication date: June 5, 2025
    Applicant: NRG THERAPEUTICS LTD
    Inventors: Neil MILLER, Richard RUTTER, Jan KULAGOWSKI, Richard MORPHY, Tammy LADDUWAHETTY, John MACLEAN, Mustafa MOROGLU, Eric TALBOT, Michael ROWLEY, Christopher G. THOMSON
  • NOVEL COMPOUNDS
    Publication number: 20240067614
    Abstract: The invention relates to compounds of formula (I): and related aspects.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 29, 2024
    Applicant: NRG Therapeutics Ltd.
    Inventors: Neil MILLER, Richard RUTTER, Jan KULAGOWSKI, Richard MORPHY, Tammy LADDUWAHETTY, John MACLEAN, Mustafa MOROGLU, Eric TALBOT, Michael ROWLEY
  • NOVEL COMPOUNDS
    Publication number: 20230312466
    Abstract: The invention relates to compounds of formula (I) and related aspects.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 5, 2023
    Applicant: NRG Therapeutics Ltd
    Inventors: Neil MILLER, Richard RUTTER, Jan KULAGOWSKI, Richard MORPHY, Tammy LADDUWAHETTY, John MACLEAN, Eric TALBOT
  • METHOD OF TREATING INFLAMMATORY DISEASES
    Publication number: 20070203216
    Abstract: The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to a method of treating a disease wherein one or more inflammatory markers are increased, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that enhances GABAA-ergic neurotransmission.
    Type: Application
    Filed: February 12, 2007
    Publication date: August 30, 2007
    Inventors: Bjarke Ebert, Timothy Bonnert, Peter Hutson, Richard Rutter